9 completed, 2 not yet recruiting, 2 terminated, 2 withdrawn. 17 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 9, Not yet recruiting 2, Terminated 2, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Infectious Encephalitis: new trials by email Literature Review of Infectious Encephalitis trials Research Report on Infectious Encephalitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers. Human monoclonal antibody TBE025, intravenous infusion - The Tick-borne Encephalitis Virus (TBEV) | Phase 1 | Not yet recruiting | Giuseppe Pantaleo | 18 | 2026-01-01 | 2026-01-29 |
| A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers V4020 - Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection | Phase 1 | Not yet recruiting | Medigen, Inc. | 39 | 2025-08-15 | 2025-07-28 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy 89 Zr-Df-crefmirlimab - Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis | Phase 1 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 15 | 2023-10-19 | 2026-06-05 |
| Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3 - Equine Encephalitis | Phase 1 | Completed | Bavarian Nordic | 45 | 2019-10-07 | 2020-08-20 |
| VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP - Venezuelan Equine Encephalitis, Western Equine Encephalitis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2019-04-02 | 2021-03-24 |
| Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine Vaccinations on Day 0, Day 28, and Day 140 - Encephalitis, Encephalitis, Viral | Phase 1 | Unknown | SRI International | 48 | 2018-07-17 | 2021-02-23 |
| Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate, 0.9% saline placebo - Venezuelan Equine Encephalitis Virus Infection | Phase 1 | Completed | Ichor Medical Systems Incorporated | 42 | 2013-12-01 | 2015-08-26 |
| Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination IXIARO - Japanese Encephalitis | Phase 1 | Withdrawn | Valneva Austria GmbH | 2012-06-01 | 2013-03-08 | |
| Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) mefloquine - Progressive Multifocal Leukoencephalopathy | Phase 1 / Phase 2 | Terminated | Biogen | 37 | 2009-01-01 | 2014-07-31 |
| Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults WN/DEN4delta30 vaccine, Placebo - West Nile Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 26 | 2008-03-01 | 2013-01-03 |
| Phase I Study of West Nile Virus Vaccine VRC-WNVDNA020-00-VP - West Nile Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2006-03-03 | 2017-07-02 |
| Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults LGT(TP21)/DEN4, Placebo - Tick-Borne Encephalitis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 28 | 2005-07-01 | 2008-01-21 |
| Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE 3526 - Venezuelan Equine Encephalitis | Phase 1 | Withdrawn | DynPort Vaccine Company LLC, A GDIT Company | 2005-07-01 | 2015-09-18 | |
| Vaccine to Prevent West Nile Virus Disease VRC-WNVDNA017-00-VP - Healthy, West Nile Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2005-03-22 | 2017-07-02 |
| Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults WN/DEN4-3'delta30, Placebo - West Nile Fever Encephalitis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2005-02-01 | 2013-01-03 |
| An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease AVI-4020 Injection - West Nile Fever | Phase 1 | Terminated | Sarepta Therapeutics, Inc. | 50 | 2004-11-01 | 2009-07-08 |
Encephalomyelitis, Venezuelan Equine (5) · West Nile Fever (5) · Alphavirus Infections (2) · Central Nervous System Diseases (2) · Encephalitis, Japanese (2) · Encephalitis, Tick-Borne (2) · Encephalomyelitis, Equine (2) · Leukoencephalopathy, Progressive Multifocal (2) · Virus Diseases (2) · Brain Diseases (1) · Central Nervous System Infections (1) · Central Nervous System Viral Diseases (1) · Encephalitis (1) · Encephalitis, Viral (1) · Encephalomyelitis (1)
Infections (17) · Neuroinflammatory Diseases (17) · Brain Diseases (16) · Central Nervous System Infections (16) · Central Nervous System Viral Diseases (16) · Encephalitis (16) · Encephalitis, Viral (16) · Nervous System Diseases (16) · Arbovirus Infections (15) · Central Nervous System Diseases (15) · Encephalitis, Arbovirus (15) · Vector Borne Diseases (15) · Virus Diseases (15) · RNA Virus Infections (14)
Infusions, Intravenous (1) · Mefloquine (1) · Saline Solution (1) · aluminum sulfate (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Bavarian Nordic (1) · Biogen (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Giuseppe Pantaleo (1) · Ichor Medical Systems Incorporated (1) · Medigen, Inc. (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · SK Bioscience Co., Ltd. (1) · SRI International (1) · Sarepta Therapeutics, Inc. (1) · Valneva Austria GmbH (1)
United States (13) · Australia (1) · Brazil (1) · Germany (1) · Italy (1) · New Zealand (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Anna Durbin, MD (2) · Anna Durbin, M.D. (1) · Carlos Fierro, MD (1) · Daniel S Reich, M.D. (1) · Grace Chen, MD (1) · Julie E Ledgerwood, DO (1) · Peter Wright, MD (1) · Sascha Goonewardena, MD (1) · Vera Kadlecek, Mag. (1)
PMID 18190252, PMID 21398392, PMID 23733308, PMID 27206386, PMID 35568049, PMID 38494412